---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-135073"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:31:38.625761+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q1 net loss narrows to $140M ($0.92 loss per share); cash $467M after $150M offering

## Summary
- Net loss attributable to common stockholders $140.2M ($0.92 diluted EPS) vs $196.4M ($1.35) in Q1 2022; revenue $1.8M flat.
- Operating expenses fell 27% YoY to $128.0M from $175.4M, reflecting cost restructuring and program reprioritization.
- Cash, equivalents, marketable securities, and restricted cash $467.0M; includes $143M net from follow-on offering closed in March 2023.
- Phase 3 ATTR-CM trial of acoramidis completed last patient last visit; topline month-30 data expected late July 2023.
- Infigratinib (achondroplasia) Phase 2 Cohort 5 showed +3.03 cm/yr annualized height velocity; 80% responders; Phase 3 run-in started.

## SEC filing metadata
- accession: 0001193125-23-135073
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312523135073/0001193125-23-135073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312523135073/d207223d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-135073
- JSON: https://secwatch.observer/filing/0001193125-23-135073.json
- Plain text: https://secwatch.observer/filing/0001193125-23-135073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.